Harbin Medisan Pharmaceutical Co Ltd (002900) — Working Capital to Net Assets Ratio
Harbin Medisan Pharmaceutical Co Ltd (002900) has a Working Capital to Net Assets ratio of -1.7% as of September 2025. Working capital of CN¥-32.18 Million (current assets of CN¥1.19 Billion minus current liabilities of CN¥1.22 Billion) is measured against net assets of CN¥1.90 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Harbin Medisan Pharmaceutical Co Ltd (002900) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Harbin Medisan Pharmaceutical Co Ltd Working Capital to Net Assets (2012–2024)
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at -1.7%, reflecting working capital of CN¥-32.18 Million against net assets of CN¥1.90 Billion CNY. Check Harbin Medisan Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Harbin Medisan Pharmaceutical Co Ltd (002900) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.9% | CN¥214.23 Million | CN¥2.16 Billion | CN¥1.47 Billion | CN¥1.26 Billion | ▼ -17.6 pp |
| 2023 | 27.5% | CN¥591.40 Million | CN¥2.15 Billion | CN¥1.44 Billion | CN¥845.03 Million | ▼ -22.5 pp |
| 2022 | 50.0% | CN¥1.03 Billion | CN¥2.05 Billion | CN¥1.62 Billion | CN¥597.73 Million | ▲ +7.9 pp |
| 2021 | 42.1% | CN¥890.58 Million | CN¥2.12 Billion | CN¥1.43 Billion | CN¥536.61 Million | ▼ -5.4 pp |
| 2020 | 47.5% | CN¥851.32 Million | CN¥1.79 Billion | CN¥1.44 Billion | CN¥588.84 Million | ▼ -4.5 pp |
| 2019 | 52.0% | CN¥962.30 Million | CN¥1.85 Billion | CN¥1.69 Billion | CN¥723.30 Million | ▼ -8.9 pp |
| 2018 | 60.8% | CN¥1.20 Billion | CN¥1.97 Billion | CN¥1.65 Billion | CN¥447.19 Million | ▲ +1.3 pp |
| 2017 | 59.5% | CN¥1.09 Billion | CN¥1.83 Billion | CN¥1.36 Billion | CN¥266.62 Million | ▲ +51.1 pp |
| 2016 | 8.4% | CN¥67.80 Million | CN¥808.17 Million | CN¥339.75 Million | CN¥271.95 Million | ▲ +0.6 pp |
| 2015 | 7.8% | CN¥56.97 Million | CN¥727.97 Million | CN¥292.83 Million | CN¥235.86 Million | ▲ +2.5 pp |
| 2014 | 5.4% | CN¥32.59 Million | CN¥609.16 Million | CN¥305.08 Million | CN¥272.49 Million | ▲ +37.2 pp |
| 2013 | -31.9% | CN¥-116.43 Million | CN¥365.13 Million | CN¥308.08 Million | CN¥424.51 Million | ▼ -24.6 pp |
| 2012 | -7.3% | CN¥-25.03 Million | CN¥342.72 Million | CN¥297.76 Million | CN¥322.79 Million | — |